These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 38990433)

  • 1. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
    Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U
    Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
    Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S
    Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
    Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R
    Leuk Lymphoma; 2024 Jul; 65(7):965-977. PubMed ID: 38501751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Momelotinib versus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis: an efficacy/safety analysis in the Japanese subgroup of the phase 3 randomized SIMPLIFY-1 trial.
    Shimoda K; Komatsu N; Matsumura I; Ikeda K; Hino M; Hidaka M; Maeda Y; Kondo T; Fujisaki T; Shoshi K; Azuma K; Fukushima R; Kawashima J; Kosugi H
    Int J Hematol; 2024 Sep; 120(3):314-324. PubMed ID: 39110143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Momelotinib for the treatment of myelofibrosis with anemia.
    Tremblay D; Mesa R
    Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
    Chifotides HT; Bose P; Verstovsek S
    J Hematol Oncol; 2022 Jan; 15(1):7. PubMed ID: 35045875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
    Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J
    J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
    Mascarenhas J; Hoffman R; Talpaz M; Gerds AT; Stein B; Gupta V; Szoke A; Drummond M; Pristupa A; Granston T; Daly R; Al-Fayoumi S; Callahan JA; Singer JW; Gotlib J; Jamieson C; Harrison C; Mesa R; Verstovsek S
    JAMA Oncol; 2018 May; 4(5):652-659. PubMed ID: 29522138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.
    Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA
    Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [JAK inhibitors for myelofibrosis: ruxolitinib and momelotinib].
    Kosugi H
    Rinsho Ketsueki; 2024; 65(8):798-809. PubMed ID: 39231711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.
    Kiladjian JJ; Vannucchi AM; Gerds AT; Gupta V; Verstovsek S; Egyed M; Platzbecker U; Mayer J; Grosicki S; Illés Á; Woźny T; Oh ST; McLornan D; Kirgner I; Yoon SS; Harrison CN; Klencke B; Huang M; Kawashima J; Mesa R
    Hemasphere; 2023 Nov; 7(11):e963. PubMed ID: 37908862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
    Gerds AT; Verstovsek S; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Oh S; Klencke BJ; Yu J; Donahue R; Kawashima J; Mesa R
    Lancet Haematol; 2023 Sep; 10(9):e735-e746. PubMed ID: 37517413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis.
    Mesa R; Harrison C; Oh ST; Gerds AT; Gupta V; Catalano J; Cervantes F; Devos T; Hus M; Kiladjian JJ; Lech-Maranda E; McLornan D; Vannucchi AM; Platzbecker U; Huang M; Strouse B; Klencke B; Verstovsek S
    Leukemia; 2022 Sep; 36(9):2261-2268. PubMed ID: 35869266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
    Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
    N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus.
    Klencke BJ; Donahue R; Gorsh B; Ellis C; Kawashima J; Strouse B
    Future Oncol; 2024 Apr; 20(11):703-715. PubMed ID: 38318719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
    Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R;
    Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
    Martí-Carvajal AJ; Anand V; Solà I
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010298. PubMed ID: 25860512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Concepts of Treatment for Patients with Myelofibrosis.
    Bose P; Alfayez M; Verstovsek S
    Curr Treat Options Oncol; 2019 Jan; 20(1):5. PubMed ID: 30675650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials.
    Verstovsek S; Mesa R; Gupta V; Lavie D; Dubruille V; Cambier N; Platzbecker U; Hus M; Xicoy B; Oh ST; Kiladjian JJ; Vannucchi AM; Gerds A; Egyed M; Mayer J; Sacha T; Kawashima J; Morris M; Huang M; Harrison C
    Blood Adv; 2023 Jul; 7(14):3582-3591. PubMed ID: 37042865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.